Live Breaking News & Updates on Prnewswire Almirall

Stay updated with breaking news from Prnewswire almirall. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Almirall, S.A.: Almirall opens a new subsidiary for the Czech Republic and Slovakia

The company is appointing David Festa as General Manager of the Czech Republic and Slovakia affiliate The new affiliate responds to Almirall's expansion strategy to support the company's gradual ....

Slovak Republic , United States , Czech Republic , Comunidad Autonoma De Cataluna , David Festa , Paolo Cionini , Prnewswire Almirall , Eu International , General Manager , Slovakia General Manager , Chief Commercial Officer ,

Almirall's Klisyri® (tirbanibulin) receives strong recommendation in American Academy of Dermatology AK guideline update

/PRNewswire/ Almirall, LLC, a global biopharmaceutical company focused on skin health, announced its microtubule inhibitor ointment, KLISYRI®. ....

United States , Comunidad Autonoma De Cataluna , Pablo Alvarez , Brian Berman , American Academy Of Dermatology Focused , Prnewswire Almirall , Spanish Stock Exchange , University Of Miami Miller School Medicine , Focused Update , Professor Emeritus , Miami Miller School , Full Prescribing Information , Actinic Keratosis , Noble Purpose , England Journal ,

Almirall achieves Core Net Sales growth of 5.1% to 436.6 MM Euros in H1

Strong operational performance during the first half of the year. The business continues to perform well boosted by the growth in Core Net Sales (+5.1%. ....

Comunidad Autonoma De Cataluna , Prnewswire Almirall , Eli Lilly , Core Net Sales , Medical Dermatology , Score Net , Net Debt , Deferred Income , Net Sales ,

Almirall: Eight out of Ten Patients Maintained Skin Clearance at One Year in Lebrikizumab Atopic Dermatitis Monotherapy Trials

/PRNewswire/ Almirall S.A. (BME: ALM) today announced topline results from one-year analyses of the efficacy and safety of lebrikizumab, an investigational. ....

New York , United States , Comunidad Autonoma De Cataluna , Prnewswire Almirall , Eli Lilly , Karl Ziegelbauer , European Union , European Medicines Agency , Drug Administration , Spanish Stock Exchange , Chief Scientific , Lotus Mallbris , Marketing Authorization Application , Eczema Area , Severity Index , Investigator Global Assessment , Pruritus Numeric Rating Scale , Dermatology Life Quality , Fast Track , Noble Purpose , Inflammatory Skin Disease Summit , Cutaneous Medicine ,

Almirall, S.A.: Almirall: Eight out of Ten Patients Maintained Skin Clearance at One Year in Lebrikizumab Atopic Dermatitis Monotherapy Trials

80% of lebrikizumab responders maintained improvements in skin clearance and disease severity at 52 weeks; lasting improvements in itch were also observedData supported both once every two week ....

New York , United States , Comunidad Autonoma De Cataluna , Prnewswire Almirall , Eli Lilly , Karl Ziegelbauer , European Union , European Medicines Agency , Drug Administration , Spanish Stock Exchange , Chief Scientific , Lotus Mallbris , Marketing Authorization Application , Eczema Area , Severity Index , Investigator Global Assessment , Pruritus Numeric Rating Scale , Dermatology Life Quality , Fast Track , Noble Purpose , Inflammatory Skin Disease Summit , Cutaneous Medicine ,